What R2 Technologies does

R2 Technologies, Inc. is a US-based medical device company founded in 2014 that develops and commercializes the Glacial Skin platform — a portfolio of CryoAesthetics devices for non-invasive aesthetic dermatology. The company's core technology is patented Cryomodulation, a precision cryotherapy method that suppresses pro-inflammatory cytokines and increases anti-inflammatory cytokines to address premature skin aging, redness, and benign skin lesions. Its flagship FDA-cleared Class II medical device, Glacial Rx (Dermal Cooling System, model C2-001), offers three treatment modalities — Glacial Glide Rx, Glacial Gloss Rx, and Glacial Freeze — and is also Health Canada-licensed. The compact Glacial fx wellness device extends the platform into spa and clinic settings with two modalities. R2 was co-founded by Pansend Life Sciences (a subsidiary of INNOVATE Corp, NYSE: VATE), Blossom Innovations, and Massachusetts General Hospital; Huadong Medicine joined as a strategic partner in 2019.

The company generates revenue through a hybrid device-plus-recurring model: one-time sales of Glacial Rx and Glacial fx systems to aesthetic practices, complemented by tiered subscription membership (Peak Program, $1,000/month base, with Elite/Plus/Base tiers tied to patient volume) that bundles unlimited consumables, warranty, preferred provider-locator placement, and training. Distribution is primarily direct sales to aesthetic practices, dermatology clinics, and medspas in North America, with expanding presence in Europe, South America, and Asia via the Huadong Medicine partnership. R2's intellectual property portfolio covers approximately 30 granted utility and design patents across the US, EP, DE, GB, JP, KR, CN, and IL, plus trademarks for CryoAesthetics, Cryomodulation, and the Glacial brand family. Scientific founders R. Rox Anderson, Henry Chan, and Dieter Manstein (Mass General Hospital), together with CEO Tim Holt and CTO Kristine Tatsutani (both ex-ZELTIQ/CoolSculpting), anchor the company's clinical and commercial leadership in cryotherapy aesthetics.

Name

R2 Technologies

Legal name

R2 Technologies, Inc.

Website

https://glacialskin.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

R2 Technologies develops and commercializes the FDA-cleared Glacial Skin platform — CryoAesthetics medical devices using patented Cryomodulation cooling technology to treat skin inflammation, redness, and benign lesions. It sells directly to aesthetic practices, dermatology clinics, and medspas globally, with a tiered Peak Program subscription for recurring consumables.

Ownership category

akta.pro rank

Product category

Aesthetic Medical Devices

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Hot/Cold Therapy Services (Cryotherapy/Ice Baths) (HSALAFAH)

akta.pro secondary industries

Cryotherapy Services (HSADAKAE), Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ)

Keywords

• Aesthetic medical devices
• Cryotherapy skin treatments
• Cryomodulation technology
• Dermatology cryo equipment
• Non-invasive aesthetic devices

Headquarters

HQ city

San Ramon

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Glacial Skin Systems: Sale of medical devices (Glacial Rx and Glacial fx systems) to aesthetic practices and healthcare providers. Revenue grew 88% in Q2 2025 vs Q2 2024.
2. Peak Program Membership: Recurring membership program with tiered benefits including unlimited consumables, free shipping, warranty coverage, preferred listing on practice locator, renewal discounts, and Glacial swag. Membership pricing at $1,000/month with discounts after first year based on usage levels.
3. Consumables and Treatment Protocols: Monthly orders of treatment consumables with early access to new products, bundled with marketing support and certification programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

R2 Technologies designs, manufactures, and sells cryotherapy-based aesthetic medical devices under the Glacial Skin brand. Its two core systems — the FDA-cleared Glacial Rx Class II medical device and the compact Glacial fx wellness device — use patented Cryomodulation™ controlled-cooling technology to deliver treatment modalities (Glacial Gloss Rx, Glacial Glide Rx, Glacial Glide Rx Combinations, Glacial Freeze) for skin inflammation, redness, benign lesion removal, and post-procedure recovery. The company also sells treatment consumables and offers the Glacial Peak Program subscription membership for providers.

Product overview

R2 Technologies offers the Glacial Skin platform, the world leader in CryoAesthetics medical devices. The platform is built around patented Cryomodulation technology and consists of two core device systems: Glacial Rx (FDA-cleared and Health Canada-licensed medical device) and Glacial fx (compact wellness device). These systems deliver multiple treatment modalities including Glacial Gloss Rx, Glacial Glide Rx, Glacial Glide Rx Combinations, and Glacial Freeze. The company also provides a membership program (Glacial Peak Program), training resources through a Provider Portal, and educational content via skinflammation.com. The technology addresses skin inflammation and premature aging through controlled cooling.

Differentiator

Problem solved

Functional benefit

Brands

• Glacial Rx: FDA-cleared and Health Canada-licensed Class II medical device for cryotherapy treatments, including Glacial Glide Rx, Glacial Gloss Rx, and Glacial Freeze modalities.
• Glacial fx
• Glacial Spa

Products and services

• Glacial Rx FDA-cleared and Health Canada-licensed Class II medical device with three treatment modalities (Glacial Glide Rx, Glacial Gloss Rx, and Glacial Freeze). Indicated for removal of benign lesions and for cooling intended for temporary reduction of pain, swelling, inflammation, hematoma from minor surgical procedures, thermal injury during laser treatments, and topical anesthetic relief of injections. Sold to aesthetic practices, dermatology clinics, and medspas.
• Glacial fx Compact countertop wellness device with two treatment modalities (Glacial Glide and Glacial Gloss). Designed for at-clinic use in medical aesthetics practices and spas for skin soothing and glow treatments using Cryomodulation™ controlled cooling technology.
• Glacial Spa Spa version of Glacial cooling technology products offering Cryomodulation™-based treatments for spa and wellness environments.
• Glacial Peak Program Recurring membership program for Glacial Skin providers with tiered benefits (Elite, Plus, Base) based on monthly treatment volume. Includes unlimited consumables, free shipping, warranty coverage, preferred listing on the provider locator, renewal discounts, and Glacial swag. Membership base pricing is $1,000/month with usage-based discounts reviewed quarterly.

Quantifiable outcome

• 88% revenue increase in Q2 2025 vs Q2 2024
• +5 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered major and core.

• Huadong Medicine Co., Ltd.majorStrategic or Co-development Partner · 1 January 2019Strategic partner brought on in 2019 to support international expansion. Represented on R2's Board of Directors by Wuming Jiang. Key partner for Asian market development.
• Blossom Innovations, LLCcoreStrategic or Co-development Partner · 1 January 2014Co-founded R2 Technologies in 2014 along with Pansend Life Sciences and Massachusetts General Hospital. Led by Irina Erenburg, PhD (Founder/CEO).
• Massachusetts General HospitalcoreStrategic or Co-development Partner · 1 January 2014Co-founded R2 Technologies in 2014 along with Pansend Life Sciences and Blossom Innovations. Provided the foundational technology and clinical research expertise.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BTL Industries (BTL Aesthetics): Direct competitor in non-invasive aesthetic devices with overlapping energy-based platforms (EmSculpt, Exilis) and a cryotherapy-adjacent product line (CryoTone). Comparable target customer of medical spas and aesthetic practices.
• Cutera: Direct peer selling energy-based aesthetic devices (lasers, RF, body sculpting) to the same dermatology and medspa channels. Overlap in clinical positioning around non-invasive skin rejuvenation and practice-level recurring consumables.
• Solta Medical: Aesthetic device maker best known for Fraxel and Thermage — directly relevant because R2's CEO Tim Holt and CSO Kristine Tatsutani came from the Fraxel/ZELTIQ world. Competes for the same provider budgets in fractional rejuvenation and skin quality.
• Cynosure: Energy-based aesthetic device company offering laser, RF, and body-contouring platforms sold to dermatology and medspa practices. Competes for the same Glacial Rx customer and similar procedural slots within practices.
• InMode: Aesthetic device company with a broad portfolio (Morpheus8, BodyTite, Evoke) targeting the same provider base of plastic surgeons, dermatologists, and medical spas. Competes directly for procedural real estate and consumables revenue per patient.
• Sciton: Private aesthetic and medical laser company with strong presence in physician offices and medspas. Competes for similar indication slots (skin rejuvenation, pigmentation, post-procedure recovery) and provider capex dollars.
• Venus Concept: Aesthetic device company with energy-based platforms and a subscription-like business model. Comparable because it also sells to non-core aesthetic practices and competes for the same lower-tier medspa segment as Glacial fx.
• Apyx Medical: Aesthetic medical device company commercializing the Renuvion platform for skin and soft tissue procedures. Competes in the same provider category and pursues adjacent cryotherapy/energy-based positioning in cosmetic practices.

Broad incumbents

• Allergan Aesthetics (AbbVie): Owns CoolSculpting (acquired ZELTIQ in 2017) and a much broader aesthetics portfolio. Highly relevant because CoolSculpting is the most established cryotherapy-based aesthetic device and many of R2's leaders built their careers inside the ZELTIQ/Allergan ecosystem.
• Lumenis: Established energy-based aesthetic and surgical device company. Larger and broader portfolio than R2, but competes for the same aesthetic practice capex and similar clinical indications in skin rejuvenation and pigmentation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xinstagram.com/glacial.skin
• YouTubeyoutube.com/channel/UCI3W0ssj_KGrf9VxxEDU3fw
• Facebookfacebook.com/GlacialRx
• LinkedInlinkedin.com/company/r2techofficial
• Instagraminstagram.com/glacial.skin
• TikToktiktok.com/@glacial.skin

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about R2 Technologies